Radical MP (Member of Parliament) helps French industry "out of its tunnel":
This article was originally published in Clinica
The French parliamentary medical technologies working group (see Clinica No 918, p 3) is to be headed by Bernard Charles, president of the Radical Green Citizens party. Mr Charles has taken a personal interest in this sector of French industry and has recently described it as "gradually emerging from a tunnel". The appointment has been welcomed by the French medical device industry association, SNITEM, which has developed a good working relationship with the MP. It has also been applauded by the US Advanced Medical Technology Association, AdvaMed, which is actively trying to help shape French policies (see this issue page 5).
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.